Table 6

Absolute and relative risk by indication and overall (pooled datasets)

Placebo

DVPX

Relative risk

Risk difference per 1,000 subjects


n/N

Absolute risk per 1,000 subjects

n/N

Absolute risk per 1,000 subjects

Incidence of events in DVPX subjects/incidence in placebo subjects

Additional DVPX subjects with events


Placebo-controlled and low-dose-controlled studies


Indication:


Epilepsy

1/204

4.90

1/208

4.81

0.98

-0.09


Psychiatric

9/726

12.40

10/926

10.80

0.87

-1.60


Migraine

0/196

0.00

0/324

0.00

-

0.00


Total

10/1,126

8.88

11/1,458

7.54

0.85

-1.34


Placebo-controlled studies


Total

9/992

9.07

11/1,137

8.29

0.91

-0.78


DVPX = divalproex sodium; n = number of subjects with events across studies; N = number of subjects treated across studies; - = relative risk cannot be calculated due to zero events in studies.

Redden et al. Annals of General Psychiatry 2011 10:1   doi:10.1186/1744-859X-10-1

Open Data